| Over a week ago | ||||
iCAD announced compelling… iCAD announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer, NMSC. In the longest-term study of Xoft Skin eBx to-date, published in the Journal of Contemporary Brachytherapy, 98.9% of patients remained recurrence-free at a median follow-up of 7.6 years. "NMSC is the most commonly diagnosed cancer in the U.S. and its incidence continues to grow worldwide.1,2 With a disease this prevalent, clinicians need proven solutions and treatment plans as individualized as each patient," said Dana Brown, President and CEO of iCAD, Inc. "Xoft Skin eBx is changing the face of non-melanoma skin cancer treatment. This study adds to the body of clinical evidence that puts Xoft Skin eBx on par with Mohs surgery with regards to safety, efficacy, and recurrence rates, but with fewer side effects and more comfort and convenience for patients. Xoft offers the potential to positively impact the lives of cancer patients and the providers who care for them on a global scale, and we are pleased to see the body of evidence supporting this technology continue to grow with the publication of this study." The long-term real-world study evaluated 180 patients with 182 NMSC lesions treated with Xoft Skin eBx at four study centers in Northern and Southern California. With a recurrence rate of 1.1% at a mean follow up of 7.5 years, researchers concluded Xoft Skin eBx is safe and effective, showing excellent long-term local control and minimal long-term toxicities. | ||||
Shares of micro-cap iCAD… Shares of micro-cap iCAD are up 18c, or 13%, to $1.55 after the U.S. Preventive Services Task Force has posted a draft recommendation statement on screening for breast cancer and now recommends that all women get screened for breast cancer every other year starting at age 40. Reference Link | ||||
iCAD announced it will… iCAD announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world's largest breast imaging conference, the Society of Breast Imaging, SBI, Symposium, taking place May 4-7 in National Harbor, MD. "While mammography screening has improved in recent decades and the introduction of digital breast tomosynthesis offers many clinical advantages, it also creates enormous amounts of data. Processing this volume of data can weigh heavily on radiologists and imaging teams," said Dana Brown, President and CEO of iCAD, Inc. "iCAD's Breast AI Suite offers a 360-degree solution of cancer detection, density assessment, and risk evaluation technologies that are uniquely positioned to address the top challenges clinicians face today. Not only is our solution clinically proven to improve accuracy and efficiency for radiologists reading mammography, it offers critical information about a woman's present and future breast health, which can help clinicians find more interval breast cancers at their earliest stage possible." | ||||
| Over a month ago | ||||
iCAD announced its… iCAD announced its "ProFound Insights, ProFound Impact" webinar series will feature Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital. The live event, titled "Elevating Accuracy Across the Board at Boca Raton Regional Hospital" will take place on Wednesday, May 24 at 10 am ET. The event will be moderated by iCAD's President and CEO, Dana Brown. To register, visit this link. During the event, Dr. Schilling will discuss the research she recently presented at the European Congress of Radiology meeting demonstrating how ProFound AI helped nine dedicated breast radiologists at the facility find 23% more cancers, without increasing the rate of recalls. She will also present a live clinical case review showcasing how ProFound AI can enhance cancer detection in a clinical setting. | ||||
iCAD announced new… iCAD announced new real-world research confirms ProFound AI has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies. One study demonstrated that ProFound AI improved radiologists' performance in detecting breast cancer and providing better accuracy, without increasing abnormal interpretation rates or the rate of recalls. The second study highlighted that the lesion and Case Scores provided by ProFound AI offer important information about the algorithm's confidence in identifying malignancy, with sequential changes in these scores offering significant additional insights. These studies were presented at the American Roentgen Ray Society meeting, which took place April 16-20 in Honolulu, HI. "The body of evidence supporting our Breast AI Suite grows as leading facilities and academic institutions worldwide continue to validate the unmatched results and benefits our technologies offer," said Dana Brown, President and CEO of iCAD, Inc. "The studies presented at the ARRS meeting confirm that ProFound AI not only improves radiologists' performance and aids in the detection of breast cancer, but also reveals valuable clues over time through Case Scores, which can help clinicians make more informed clinical decisions and personalize patient care." | ||||
iCAD announced the Board… iCAD announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer, CFO, effective immediately, as well as Vasu Avadhanula as Chief Product Officer, CPO, and Michelle Strong as Chief Operations Officer, COO, effective May 1. Eric Lonnqvist Appointed as Chief Financial Officer: Lonnqvist brings more than 15 years of finance and accounting experience in the medical device and technology industries. Vasu Avadhanula joins as Chief Product Officer: Avadhanula brings more than 25 years of product development, business analytics, and technology innovation experience in the healthcare and technology industries. Michelle Strong joins as Chief Operations Officer: Strong joins the Company with more than 25 years of experience in marketing and healthcare technology, most recently serving as VP of Marketing Strategy at Susan G. Komen. | ||||
JMP Securities lowered… JMP Securities lowered the firm's price target on iCAD to $4 from $7 and keeps an Outperform rating on the shares. The quarterly numbers were in line with those preannounced in March, and new CEO Dana Brown did a "good job" highlighting her past management experiences, focusing on driving additional value via the subscription-based sales model in Detection, while simultaneously exploring strategic options on the Therapy side, the analyst tells investors in a research note. While the potential long-term benefits of the new model adoption are easy to understand, the near-to-medium term could remain a bit choppy through this transition phase, the firm says. | ||||
iCAD announced new… iCAD announced new clinical evidence published in the Journal of Clinical Oncology found ProFound AI Risk for 2D Mammography is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model, for both short-term and long-term risk assessments. Using the unique KARolinska MAmmography Project for Risk Prediction of Breast Cancer screening cohort, researchers compared ProFound AI Risk with Tyrer-Cuzick v8 in a case-cohort study of 8,604 women aged 40-74 years throughout a 10-year follow up. ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women - regardless of menopausal status, breast density, and family history of breast cancer - with an area under the curve ranging from 0.74-0.65 for ProFound AI Risk, compared to 0.62-0.60 for Tyrer-Cuzick v8. iCAD's Breast AI Suite offers a 360-degree solution of clinically proven cancer detection, density assessment, and risk evaluation technologies. The latest addition to iCAD's Breast AI Suite, ProFound AI Risk, is the world's first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram.6,7 Available for both 2D and 3D mammography, it uniquely combines age, breast density and subtle mammographic features, offering superior performance and accuracy in assessing short-term risk compared to traditional, commonly-used breast cancer risk models. ProFound AI Risk complements traditional risk models and is easy for clinicians and medical facilities to adopt, as it only requires the images from a 2D or 3D mammogram, with no questionnaires, portals, or staff required to implement. | ||||
Lake Street lowered the… Lake Street lowered the firm's price target on iCAD to $2.50 from $5 and keeps a Buy rating on the shares after the company announced Q4 results. "Clearly, things have not gone well for iCAD over the prior 1.5 years" and while the situation comes with risks, "we are hopeful we are reaching rock bottom," said Lake Street, which adds that it is "hopeful with the new management and board reorganization the company can execute on its primary initiatives." | ||||
BTIG lowered the… BTIG lowered the firm's price target on iCAD to $3 from $4 but keeps a Buy rating on the shares. The company's pledge to reduce spend and reach profitability is encouraging, but BTIG is skeptical that revenue can grow meaningfully near-term given the deep cuts to the workforce, exploration of strategic options for the Xoft Therapy business, and continued shift toward a subscription sales model, the analyst tells investors in a research note. Despite workforce reductions, ICAD has also not reduced sales personnel headcount in the Detection business, and the updated compensation incentives as well as new selling metrics being put in place by the new head of U.S. Commercial Sales in AI can help preserve the subscription sales strategy, BTIG added. | ||||
